BiotechTube
Finvector Vision Therapies

Finvector Vision Therapies

Kuopio, Finland· Est.
finvector.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

FinVector is a privately held, commercial-stage CDMO and therapeutics company with a core focus on viral vector manufacturing for gene therapies. The company has established itself as an FDA-approved manufacturer, currently producing a commercial gene therapy for bladder cancer, indicating it is revenue-generating. Its business model combines contract manufacturing services with a potential proprietary therapeutic focus, supported by a strong leadership team with ties to Ferring Pharmaceuticals. FinVector's strategic position in the high-growth gene therapy manufacturing sector is bolstered by its modern facility and experienced team.

OphthalmologyOncology

Technology Platform

cGMP manufacturing platform for viral-based gene therapy products (viral vectors), leveraging over 30 years of collective scientific and process expertise.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The global shortage of cGMP viral vector manufacturing capacity presents a major growth opportunity for FinVector as a specialized CDMO.
The expanding gene therapy pipeline across the industry drives sustained demand for its services.
Furthermore, the commercial success and potential label expansions of its flagship bladder cancer therapy provide a stable core revenue stream.

Risk Factors

The company faces significant client concentration risk, being heavily reliant on manufacturing for a single commercial product.
Operational risks include the complexity of viral vector manufacturing, potential for batch failures, and the need for continuous regulatory compliance.
Competition in the CDMO space is increasing from both large pharma and dedicated contract manufacturers.

Competitive Landscape

FinVector competes in the viral vector CDMO space against large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as other specialized biotech CDMOs. Its competitive advantages include FDA-approved status, a modern facility, deep expertise linked to a commercial product, and strategic backing from Ferring. Its Nordic location may also differentiate it in the European market.

More companies in Cell & Gene Therapy →More companies in Finland →